• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Translational Oncology >Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis
【24h】

Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis

机译：弥散加权MRI作为肿瘤放射治疗反应异质性的生物标记：基于体积直方图分析的对比研究对比基于体素的功能性扩散图分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

RATIONALE:Treatment of glioblastoma (GBM) remains challenging due in part to its histologic intratumoral heterogeneity that contributes to its overall poor treatment response. Our goal was to evaluate a voxel-based biomarker, the functional diffusion map (fDM), as an imaging biomarker to detect heterogeneity of tumor response in a radiation dose escalation protocol using a genetically engineered murine GBM model.EXPERIMENTAL DESIGN:Twenty-four genetically engineered murine GBM models [Ink4a-Arf-/-/Ptenloxp/loxp/Ntv-a RCAS/PDGF(+)/Cre(+)] were randomized in four treatment groups (n= 6 per group) consisting of daily doses of 0, 1, 2, and 4 Gy delivered for 5 days. Contrast-enhanced T1-weighted and diffusion-weighted magnetic resonance imaging (MRI) scans were acquired for tumor delineation and quantification of apparent diffusion coefficient (ADC) maps, respectively. MRI experiments were performed daily for a week and every 2 days thereafter. For each animal, the area under the curve (AUC) of the percentage change of the ADC (AUCADC) and that of the increase in fDM values (AUCfDM+) were determined within the first 5 days following therapy initiation.RESULTS:Animal survival increased with increasing radiation dose. Treatment induced a dose-dependent increase in tumor ADC values. The strongest correlation between survival and ADC measurements was observed using the AUCfDM+metric (R2= 0.88).CONCLUSION:This study showed that the efficacy of a voxel-based imaging biomarker (fDM) was able to detect spatially varying changes in tumors, which were determined to be a more sensitive predictor of overall responseversuswhole-volume tumor measurements (AUCADC). Finally, fDM provided for visualization of treatment-associated spatial heterogeneity within the tumor.
机译：理由：胶质母细胞瘤（GBM）的治疗仍然具有挑战性，部分原因是其组织学上的肿瘤内异质性导致整体治疗反应较差。我们的目标是使用基因工程鼠类GBM模型评估基于体素的生物标记物功能扩散图（fDM）作为成像生物标记物，以检测辐射剂量递增方案中肿瘤反应的异质性。实验设计：二十四个基因工程鼠GBM模型[Ink4a-Arf-/-/ Ptenloxp / loxp / Ntv-a RCAS / PDGF（+）/ Cre（+）]随机分为四个治疗组（每组n = 6），每日剂量为0 ，1、2和4 Gy交付了5天。分别获取对比增强的T1加权和弥散加权磁共振成像（MRI）扫描，以描绘肿瘤并量化表观弥散系数（ADC）图。每天进行MRI实验，持续一周，此后每2天进行一次。对于每只动物，在治疗开始后的前5天内确定ADC的百分比变化的曲线下面积（AUCADC）和fDM值增加的曲线下面积（AUCfDM +）。增加辐射剂量。治疗引起肿瘤ADC值的剂量依赖性增加。使用AUCfDM + metric（R2 = 0.88）观察到生存率与ADC测量之间的最强相关性。结论：这项研究表明，基于体素的成像生物标记物（fDM）的功效能够检测肿瘤的空间变化，从而被确定为整体反应与整个体积肿瘤测量（AUCADC）的更敏感的预测指标。最后，fDM提供了可视化的肿瘤内与治疗相关的空间异质性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号